These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 30136462)

  • 1. [SGLT2 inhibitor or GLP-1 receptor agonist in a type 2 diabetic patient with cardiovascular disease ?].
    Scheen AJ; Paquot N
    Rev Med Suisse; 2018 Aug; 14(615):1460-1465. PubMed ID: 30136462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists.
    Scheen AJ
    Diabetes Res Clin Pract; 2018 Sep; 143():88-100. PubMed ID: 29944969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [SGLT2 inhibitor or GLP-1 receptor agonist in a patient with type 2 diabetes and cardiovascular disease ?].
    Scheen AJ; Paquot N
    Rev Med Liege; 2018 Jan; 73(1):43-50. PubMed ID: 29388411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential unrealized mortality benefit of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transport-2 inhibitors: A report from the Veterans Health Administration Clinical Assessment, Reporting and Tracking program.
    Salahuddin T; Richardson V; McNeal DM; Henderson K; Hess PL; Raghavan S; Saxon DR; Valle JA; Waldo SW; Ho PM; Schwartz GG
    Diabetes Obes Metab; 2021 Jan; 23(1):97-105. PubMed ID: 32902128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM).
    Gourdy P; Darmon P; Dievart F; Halimi JM; Guerci B
    Cardiovasc Diabetol; 2023 Apr; 22(1):79. PubMed ID: 37005640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020.
    Adhikari R; Jha K; Dardari Z; Heyward J; Blumenthal RS; Eckel RH; Alexander GC; Blaha MJ
    J Am Heart Assoc; 2022 May; 11(9):e023811. PubMed ID: 35475341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Combination therapy with SGLT2 inhibitor and GLP-1 receptor agonist in type 2 diabetes].
    Scheen AJ
    Rev Med Suisse; 2019 Aug; 15(659):1436-1441. PubMed ID: 31436058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.
    Hussein H; Zaccardi F; Khunti K; Seidu S; Davies MJ; Gray LJ
    Diabet Med; 2019 Apr; 36(4):444-452. PubMed ID: 30653708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.
    Dong YH; Chang CH; Lin JW; Yang WS; Wu LC; Toh S
    Diabetes Obes Metab; 2022 Aug; 24(8):1623-1637. PubMed ID: 35491533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes.
    Wright AK; Carr MJ; Kontopantelis E; Leelarathna L; Thabit H; Emsley R; Buchan I; Mamas MA; van Staa TP; Sattar N; Ashcroft DM; Rutter MK
    Diabetes Care; 2022 Apr; 45(4):909-918. PubMed ID: 35100355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cardiovascular protection of patients with type 2 diabetes : from EMPA-REG OUTCOME to LEADER].
    Scheen AJ; Wallemacq C; Jandrain B; Ernest P
    Rev Med Suisse; 2016 Aug; 12(527):1370-1375. PubMed ID: 28671791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns.
    Lim S; Kim KM; Nauck MA
    Trends Endocrinol Metab; 2018 Apr; 29(4):238-248. PubMed ID: 29463450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.
    Med Lett Drugs Ther; 2019 Feb; 61(1566):26-28. PubMed ID: 30845101
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative safety and cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in nursing homes.
    Riester MR; Zullo AR; Joshi R; Daiello LA; Hayes KN; Ko D; Kim DH; Munshi M; Berry SD
    Diabetes Obes Metab; 2024 Aug; 26(8):3403-3417. PubMed ID: 38779879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review.
    Honigberg MC; Chang LS; McGuire DK; Plutzky J; Aroda VR; Vaduganathan M
    JAMA Cardiol; 2020 Oct; 5(10):1182-1190. PubMed ID: 32584928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: A real-world study in two Italian cohorts.
    Baviera M; Genovese S; Lepore V; Colacioppo P; Robusto F; Tettamanti M; D'Ettorre A; Avanzini F; Fortino I; Nicolucci A; Roncaglioni MC; Giorgino F
    Diabetes Obes Metab; 2021 Jul; 23(7):1484-1495. PubMed ID: 33606897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease.
    ; Tsukamoto S; Kobayashi K; Toyoda M; Tone A; Kawanami D; Suzuki D; Tsuriya D; Machimura H; Shimura H; Wakui H; Takeda H; Yokomizo H; Takeshita K; Chin K; Kanasaki K; Miyauchi M; Saburi M; Morita M; Yomota M; Kimura M; Hatori N; Nakajima S; Ito S; Murata T; Matsushita T; Furuki T; Hashimoto T; Umezono T; Muta Y; Takashi Y; Tamura K
    Diabetes Obes Metab; 2024 Aug; 26(8):3248-3260. PubMed ID: 38764356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease.
    Li J; Albajrami O; Zhuo M; Hawley CE; Paik JM
    Clin J Am Soc Nephrol; 2020 Nov; 15(11):1678-1688. PubMed ID: 32518100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.